NephroNet

06/18/2026

🧬 New Hope for IgA Nephropathy Patients!
The phase 2 ENVISION trial shows that sibeprenlimab, an APRIL-targeting monoclonal antibody, significantly reduced proteinuria in high-risk patients with IgA nephropathy who had already received standard care.
📉 At 12 months:
✔️ Up to 62% reduction in proteinuria with sibeprenlimab
✔️ Slower decline in kidney function (eGFR) compared to placebo
✔️ Similar safety profile between treatment and placebo groups
These results suggest sibeprenlimab may offer a novel, effective therapy for IgA nephropathy. 💡
🔗 Learn more: https://ow.ly/cwTv50WMnJr

06/15/2026

❓ True or False: Kidneys only help with filtering waste. (Answer in the comments!)

06/12/2026

Healthy Eating for Adults with Chronic Kidney Disease

Advice about what to eat and drink to slow chronic kidney disease (CKD), including suggestions to work with a dietitian to create and adjust meal plans.

06/09/2026

How NKF Got Here: Kidney Care in the 2000s

Free kidney screenings, improved Medicare coverage, and policy wins defined kidney care in the 2000s. Read what changed and why it matters.

06/04/2026

Life is all about balance — just ask your nephrons.

06/01/2026

🩺💡 Nephrology Insight of the Week

🔍 Kidney health is more than numbers — it’s about understanding the interplay between heart, immune system, and renal function. From IgA nephropathy research uncovering new treatment targets, to innovative trials using advanced diagnostics like mNGS for faster infection detection, the future of kidney care is precision-driven.

💬 Why it matters:
Early detection, targeted therapies, and individualized treatment plans mean better outcomes for patients with complex kidney diseases.
✅ Stay informed.
✅ Support research.
✅ Advocate for kidney health.

05/28/2026

🧠💊 Ticagrelor vs. Clopidogrel in Stroke Patients with CYP2C19 LOF — Age & Kidney Function Matter

Objective:
Compare efficacy and safety of ticagrelor-aspirin vs. clopidogrel-aspirin in CYP2C19 loss-of-
function carriers with stroke, stratified by age and renal function.

Study details:
Data from CHANCE-2 trial.
Primary endpoint: new stroke within 90 days.
Safety endpoint: bleeding events.
Stratification by age (90 mL/min/1.73 m²
Mild impairment: eGFR 60–89
Moderate/severe impairment: eGFR 90):
Ticagrelor significantly reduced stroke risk in both ≥65 years (HR 0.53, p = 0.008) and

05/26/2026

🥦 What’s your go-to kidney-friendly food or healthy snack?

05/25/2026

United in remembrance. Stronger together.

05/22/2026

Proof That No Summit Is Too High After Transplant

After receiving a kidney transplant from his father in 2022, Pemba Sherpa—a 37-year-old from Nepal—refused to let chronic illness define his future. Determined to show what’s possible after transplant, he trained relentlessly and, in May 2025, became the first kidney transplant recipient to su...